Drug candidates may fail in clinical trials for many reasons. Biomarker-guided clinical trial design can mitigate the risk of failure and enable more informative clinical experiments regardless of outcomes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Drug repurposing: a systematic review on root causes, barriers and facilitators
BMC Health Services Research Open Access 29 July 2022
-
The “rights” of precision drug development for Alzheimer’s disease
Alzheimer's Research & Therapy Open Access 31 August 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010).
Chan, A. C. & Behrens, T. W. Personalizing medicine for autoimmune and inflammatory diseases. Nat. Immunol. 14, 106–109 (2013).
Arron, J. R., Townsend, M. J., Keir, M. E., Yaspan, B. L. & Chan, A. C. Stratified medicine in inflammatory disorders: from theory to practice. Clin. Immunol. 161, 11–22 (2015).
Smith, K. G. & Clatworthy, M. R. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10, 328–343 (2010).
Tzouvelekis, A., Herazo-Maya, J., Sakamoto, K. & Bouros, D. Biomarkers in the evaluation and management of idiopathic pulmonary fibrosis. Curr. Top. Med. Chem. 16, 1587–1598 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.J.T. and J.R.A. are employees of Genentech Inc. and hold stock and options in the Roche Group.
Supplementary information
Supplementary information S1 (figure)
Supplementary figure legend (PDF 308 kb)
Related links
Rights and permissions
About this article
Cite this article
Townsend, M., Arron, J. Reducing the risk of failure: biomarker-guided trial design. Nat Rev Drug Discov 15, 517–518 (2016). https://doi.org/10.1038/nrd.2016.124
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.124
This article is cited by
-
Drug repurposing: a systematic review on root causes, barriers and facilitators
BMC Health Services Research (2022)
-
The “rights” of precision drug development for Alzheimer’s disease
Alzheimer's Research & Therapy (2019)
-
Emerging targets of disease-modifying therapy for systemic sclerosis
Nature Reviews Rheumatology (2019)
-
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Nature Reviews Drug Discovery (2018)